Prescription Sleep Medications, Side by Side

Which prescription sleeping pill is best?

No prescription sleeping pill is clearly best, and any page that names a winner is overselling. When a sleep-medicine guideline went drug by drug, it could offer only weak recommendations for or against each agent, because the evidence for every one is limited 1Ref 1Sateia MJ, Buysse DJ, Krystal AD, Neubauer DN, Heald JL (2017).Clinical Practice Guideline for the Pharmacologic Treatment of Chronic Insomnia in Adults: An American Academy of Sleep Medicine Clinical Practice Guideline.AASM drug-by-drug guideline giving only weak recommendations for or against individual agents, and suggesting against melatonin, trazodone, and over-the-counter antihistamines for chronic insomnia; used for the weak-evidence framing and the against-melatonin/antihistamine claims.. A separate evidence review found the benefits real but modest, set against a consistent trickle of side effects and harms 2Ref 2Wilt TJ, MacDonald R, Brasure M, et al. (2016).Pharmacologic Treatment of Insomnia Disorder: An Evidence Report for a Clinical Practice Guideline by the American College of Physicians.Systematic evidence review documenting modest, mostly short-term benefits of insomnia drugs alongside adverse-event and harm concerns; used for the benefits-are-modest-and-carry-harms framing.. Best, then, is personal — a match to one person's risks, not a ranking.

No single sleeping pill is best; the choice is a match to the person, not a ranking.

That is not a reason to dismiss these drugs. It is a reason to choose on the right basis. The features that separate one option from another are rarely about raw sleep-inducing power, where they land in a broadly similar range. They are about how a drug behaves the next morning, whether the body comes to depend on it, and what specific safety signals it carries. A useful comparison lines those up — and it starts one step back, because the strongest recommendation in the field is not for a pill at all.

That framing is not a dodge. It is the single most useful thing to know before comparing brands, because it changes the question from which pill wins to when a pill is the right tool at all — and, once that is settled, which trade-offs a person is most willing to accept.

Why the first-line answer is not a pill

Before comparing medications, it is worth naming what outranks all of them. Cognitive behavioral therapy for insomnia carries a strong guideline recommendation as the first-line treatment for chronic insomnia, and the same guidelines note that sleep-hygiene advice on its own is not a treatment 3Ref 3Edinger JD, Arnedt JT, Bertisch SM, et al. (2021).Behavioral and psychological treatments for chronic insomnia disorder in adults: an American Academy of Sleep Medicine clinical practice guideline.AASM guideline giving a strong recommendation for multicomponent CBT-I and recommending that sleep hygiene not be used as a standalone treatment; used for the CBT-I-is-first-line and sleep-hygiene-alone-is-not-a-treatment claims.. The reason is durability: a drug helps while you take it, whereas the therapy's benefit tends to outlast the course. On CBT-I vs sleeping pills, that difference is the whole point.

This reframes the comparison that follows. A prescription hypnotic is a reasonable tool — for a short, defined stretch, alongside therapy, or when therapy is not available or has not been enough. It is far weaker as a permanent answer, which is the honest context for asking whether sleeping pills for insomnia fix the underlying problem or mostly quiet the symptom. With that established, here is how the drug options actually differ.

The prescription options, side by side

Prescription sleep medicines fall into a handful of groups, and they differ more in safety profile than in strength. The table below compares them on the terms that tend to decide a good fit: how solid the evidence is, whether the body can come to depend on the drug, next-morning impairment, and any specific safety warnings. None of these is a dose or a recommendation — the choice belongs to a prescriber who knows the person.

Each row rests on the same evidence base the rest of this page cites: the guideline's weak, drug-by-drug recommendations 1Ref 1Sateia MJ, Buysse DJ, Krystal AD, Neubauer DN, Heald JL (2017).Clinical Practice Guideline for the Pharmacologic Treatment of Chronic Insomnia in Adults: An American Academy of Sleep Medicine Clinical Practice Guideline.AASM drug-by-drug guideline giving only weak recommendations for or against individual agents, and suggesting against melatonin, trazodone, and over-the-counter antihistamines for chronic insomnia; used for the weak-evidence framing and the against-melatonin/antihistamine claims., the FDA's boxed warning on the z-drugs 4Ref 4US Food and Drug Administration (2019).Certain Prescription Insomnia Medicines: New Boxed Warning — Due to Risk of Serious Injuries Caused by Sleepwalking, Sleep Driving and Engaging in Other Activities While Not Fully Awake.FDA (2019) boxed warning and contraindication for eszopiclone, zaleplon, and zolpidem due to rare but serious injuries from complex sleep behaviors that can occur even after a single dose; used for the z-drug boxed-warning claim. and its separate caution on next-morning impairment 5Ref 5US Food and Drug Administration (2013).Risk of next-morning impairment after use of insomnia drugs; FDA requires lower recommended doses for certain drugs containing zolpidem (Ambien, Ambien CR, Edluar, and Zolpimist).FDA (2013) lowered the recommended dose of zolpidem, especially for women, because of next-morning impairment from morning blood levels high enough to impair driving; used for the next-morning-driving-impairment and dose-reduction claims, without stating any dose figure., the off-label and thinly evidenced use of trazodone 6Ref 6Jaffer KY, Chang T, Vanle B, et al. (2017).Trazodone for Insomnia: A Systematic Review.Systematic review of low-dose trazodone for insomnia showing modest efficacy but limited high-quality data, widely used off-label despite no FDA insomnia indication; used for the trazodone-is-off-label-with-modest-evidence claim., and the guideline's suggestion against melatonin and over-the-counter antihistamines for chronic insomnia 1Ref 1Sateia MJ, Buysse DJ, Krystal AD, Neubauer DN, Heald JL (2017).Clinical Practice Guideline for the Pharmacologic Treatment of Chronic Insomnia in Adults: An American Academy of Sleep Medicine Clinical Practice Guideline.AASM drug-by-drug guideline giving only weak recommendations for or against individual agents, and suggesting against melatonin, trazodone, and over-the-counter antihistamines for chronic insomnia; used for the weak-evidence framing and the against-melatonin/antihistamine claims.. The z-drugs — the group most people mean by sleeping pills — get their own section next.

One caution cuts across every row: the numbers that would let you rank these drugs cleanly against each other simply do not exist in strong form. Head-to-head trials are few, follow-up is short, and much of what is known comes from separate studies that cannot be lined up neatly. That is why a responsible comparison talks in terms of safety signals and trade-offs rather than a leaderboard — and why the same evidence review that found real benefits also called them modest 2Ref 2Wilt TJ, MacDonald R, Brasure M, et al. (2016).Pharmacologic Treatment of Insomnia Disorder: An Evidence Report for a Clinical Practice Guideline by the American College of Physicians.Systematic evidence review documenting modest, mostly short-term benefits of insomnia drugs alongside adverse-event and harm concerns; used for the benefits-are-modest-and-carry-harms framing..

Z-drugs and the boxed warning

The z-drugs — zolpidem, zaleplon, and eszopiclone — are the medicines most people picture as modern sleeping pills, and they carry the field's most serious safety flag. In 2019 the FDA added a boxed warning, its strongest, after reports of people sleepwalking, sleep-driving, and doing other complex sleep behaviors while not fully awake, occasionally with severe injuries and sometimes after a single dose 4Ref 4US Food and Drug Administration (2019).Certain Prescription Insomnia Medicines: New Boxed Warning — Due to Risk of Serious Injuries Caused by Sleepwalking, Sleep Driving and Engaging in Other Activities While Not Fully Awake.FDA (2019) boxed warning and contraindication for eszopiclone, zaleplon, and zolpidem due to rare but serious injuries from complex sleep behaviors that can occur even after a single dose; used for the z-drug boxed-warning claim.. It is rare, but it is the warning that most shapes prescribing.

The practical upshot is not that these drugs are off-limits; many people take them without incident. It is that they are used at the lowest effective dose for the shortest sensible time, and that any episode of doing something while asleep is a reason to stop and call the prescriber. This is also the group where next-morning effects were concerning enough for regulators to act on separately, which is the next distinction worth understanding.

Next-morning grogginess and driving

A drug that works overnight can still be in the system at breakfast, and that is the second safety theme. In 2013 the FDA lowered the recommended dose of zolpidem — especially for women, who tend to clear it more slowly — because morning blood levels could stay high enough to impair driving without the person feeling impaired 5Ref 5US Food and Drug Administration (2013).Risk of next-morning impairment after use of insomnia drugs; FDA requires lower recommended doses for certain drugs containing zolpidem (Ambien, Ambien CR, Edluar, and Zolpimist).FDA (2013) lowered the recommended dose of zolpidem, especially for women, because of next-morning impairment from morning blood levels high enough to impair driving; used for the next-morning-driving-impairment and dose-reduction claims, without stating any dose figure.. Grogginess is not just unpleasant; when it dulls reaction time behind the wheel, it becomes a genuine safety issue.

This is where the differences between drugs get practical. Agents that leave the body quickly tend to cause less next-day carryover; longer-acting ones can linger. The felt experience — waking clear-headed versus foggy — is one of the most reliable things a person can report back to a prescriber, and it often matters more to real life than any trial's average. The sleeping pill risks in older adults tilt this trade-off hardest, since a fall or a foggy morning carries more weight in an aging body.

Dependence, and coming off later

Any comparison has to account for the exit, not just the entry. Benzodiazepines and, to a lesser degree, the z-drugs can lead the body to adapt with regular use, so tolerance and dependence build and stopping abruptly can bring a rebound or a withdrawal reaction. That does not make them dangerous to start; it makes the plan to eventually stop part of the decision. Coming off sleeping pills is done by tapering, not quitting overnight.

This is a real point of difference between groups. The orexin blockers and low-dose sedating antidepressants are generally considered to carry less of this dependence risk, which is part of why they appeal for longer courses — though their own evidence remains limited. Weighing how hard a drug is to leave against how well it works while taken is exactly the kind of trade a prescriber balances person by person, rather than settling once for everyone.

The practical takeaway is to treat the exit as part of the entry decision. Agreeing up front on how long a course will run, and what stepping down will look like, keeps a short-term aid from quietly becoming a standing one. That plan is far easier to make at the start than to improvise a year in.

Matching the choice to the person

Because no option wins outright, the real work is matching a drug's trade-offs to a particular person — which is why the same prescription can be right for one patient and wrong for the next. A few features tend to steer the decision. Whether the trouble is falling asleep or staying asleep points toward drugs that act fast and briefly versus ones that carry through the night. Age shifts the math, since grogginess and falls carry more weight later in life. So does the rest of the medicine cabinet: other sedatives, alcohol, and some painkillers stack their effects.

A person's day matters as much as their night. Someone who drives professionally, cares for a child overnight, or operates machinery has more to lose from next-morning impairment, which is exactly the risk regulators acted on for zolpidem 5Ref 5US Food and Drug Administration (2013).Risk of next-morning impairment after use of insomnia drugs; FDA requires lower recommended doses for certain drugs containing zolpidem (Ambien, Ambien CR, Edluar, and Zolpimist).FDA (2013) lowered the recommended dose of zolpidem, especially for women, because of next-morning impairment from morning blood levels high enough to impair driving; used for the next-morning-driving-impairment and dose-reduction claims, without stating any dose figure.. A history of dependence, or a strong wish to avoid it, argues against the more habit-forming options. None of this is something to settle from a web page. It is the substance of the conversation a prescriber has — and going in knowing which trade-offs matter most to you makes that conversation far more useful than any ranking could.

Off-label and over-the-counter options

Not every pill used for sleep is a licensed sleeping pill. Low-dose trazodone, a sedating antidepressant, is prescribed off-label very widely despite modest, low-quality evidence and no FDA approval for insomnia 6Ref 6Jaffer KY, Chang T, Vanle B, et al. (2017).Trazodone for Insomnia: A Systematic Review.Systematic review of low-dose trazodone for insomnia showing modest efficacy but limited high-quality data, widely used off-label despite no FDA insomnia indication; used for the trazodone-is-off-label-with-modest-evidence claim.. Sleep-medicine guidelines actually suggest against several popular choices for chronic insomnia — melatonin, the antihistamines in over-the-counter sleep aids, and a few herbal remedies — because the evidence does not support them 1Ref 1Sateia MJ, Buysse DJ, Krystal AD, Neubauer DN, Heald JL (2017).Clinical Practice Guideline for the Pharmacologic Treatment of Chronic Insomnia in Adults: An American Academy of Sleep Medicine Clinical Practice Guideline.AASM drug-by-drug guideline giving only weak recommendations for or against individual agents, and suggesting against melatonin, trazodone, and over-the-counter antihistamines for chronic insomnia; used for the weak-evidence framing and the against-melatonin/antihistamine claims..

This matters because natural or over-the-counter reads as safer, and for chronic insomnia the trade is often worse evidence for a comparable list of side effects — antihistamines, for instance, cause next-day grogginess of their own. The takeaway is not that any of these can never help; it is that being off-label or non-prescription does not make a choice better-supported. Whether melatonin has a real role at all is a separate question worth its own careful look, but for ordinary chronic insomnia the best-evidenced option remains the one that is not a pill.

That does not settle any individual case. It simply means the burden of proof sits differently than the marketing implies, and a prescriber is the person to weigh it with — which is the honest note to end a comparison on.